Theseus Pharmaceuticals Stock Probability Of Bankruptcy
| THRXDelisted Stock | USD 4.06 0.00 0.00% |
Theseus |
Theseus Pharmaceuticals Company probability of bankruptcy Analysis
Theseus Pharmaceuticals' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Theseus Pharmaceuticals Probability Of Bankruptcy | Over 100% |
Most of Theseus Pharmaceuticals' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Theseus Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Theseus Pharmaceuticals probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Theseus Pharmaceuticals odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Theseus Pharmaceuticals financial health.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
CompetitionBased on the latest financial disclosure, Theseus Pharmaceuticals has a Probability Of Bankruptcy of 100%. This is 131.0% higher than that of the Biotechnology sector and 82.35% higher than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 151.07% lower than that of the firm.
Theseus Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Theseus Pharmaceuticals' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Theseus Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Theseus Pharmaceuticals by comparing valuation metrics of similar companies.Theseus Pharmaceuticals is currently under evaluation in probability of bankruptcy category among related companies.
Theseus Fundamentals
| Return On Equity | -0.26 | |||
| Return On Asset | -0.18 | |||
| Current Valuation | (20.19 M) | |||
| Shares Outstanding | 44.65 M | |||
| Shares Owned By Insiders | 2.55 % | |||
| Shares Owned By Institutions | 93.28 % | |||
| Number Of Shares Shorted | 401.68 K | |||
| Price To Earning | 737.67 X | |||
| Price To Book | 0.81 X | |||
| EBITDA | (66.44 M) | |||
| Net Income | (56.61 M) | |||
| Cash And Equivalents | 212.43 M | |||
| Cash Per Share | 5.55 X | |||
| Total Debt | 3.98 M | |||
| Debt To Equity | 0.02 % | |||
| Current Ratio | 27.54 X | |||
| Book Value Per Share | 5.17 X | |||
| Cash Flow From Operations | (49.63 M) | |||
| Short Ratio | 0.82 X | |||
| Earnings Per Share | (1.34) X | |||
| Target Price | 5.25 | |||
| Number Of Employees | 38 | |||
| Beta | 3.98 | |||
| Market Capitalization | 181.28 M | |||
| Total Asset | 222.45 M | |||
| Retained Earnings | (112.19 M) | |||
| Working Capital | 190.99 M | |||
| Current Asset | 223.75 M | |||
| Current Liabilities | 11.28 M | |||
| Z Score | 26.67 | |||
| Net Asset | 222.45 M |
About Theseus Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Theseus Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Theseus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Theseus Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Consideration for investing in Theseus Stock
If you are still planning to invest in Theseus Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Theseus Pharmaceuticals' history and understand the potential risks before investing.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |